Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 307

1.

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.

Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR.

Psychopharmacology (Berl). 2018 Oct;235(10):2915-2927. doi: 10.1007/s00213-018-4981-x. Epub 2018 Jul 30.

PMID:
30062577
2.

Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.

Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW.

J Psychopharmacol. 2018 Jul;32(7):756-769. doi: 10.1177/0269881118780612. Epub 2018 Jun 25.

PMID:
29938565
3.

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE.

Neuropharmacology. 2018 Jun 5. pii: S0028-3908(18)30229-6. doi: 10.1016/j.neuropharm.2018.05.012. [Epub ahead of print] Review.

4.

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR.

Psychopharmacology (Berl). 2018 Feb;235(2):521-534. doi: 10.1007/s00213-017-4769-4. Epub 2017 Nov 7.

PMID:
29116367
5.

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.

Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA.

J Psychopharmacol. 2018 Jan;32(1):49-69. doi: 10.1177/0269881117731279. Epub 2017 Oct 11.

6.

Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.

Barrett FS, Robbins H, Smooke D, Brown JL, Griffiths RR.

Front Psychol. 2017 Jul 25;8:1238. doi: 10.3389/fpsyg.2017.01238. eCollection 2017.

7.

Neuroticism is associated with challenging experiences with psilocybin mushrooms.

Barrett FS, Johnson MW, Griffiths RR.

Pers Individ Dif. 2017 Oct 15;117:155-160. doi: 10.1016/j.paid.2017.06.004. Epub 2017 Jun 7.

8.

Potential Therapeutic Effects of Psilocybin.

Johnson MW, Griffiths RR.

Neurotherapeutics. 2017 Jul;14(3):734-740. doi: 10.1007/s13311-017-0542-y. Review.

9.

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.

Barrett FS, Griffiths RR.

Curr Top Behav Neurosci. 2018;36:393-430. doi: 10.1007/7854_2017_474. Review.

PMID:
28401522
10.

The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016.

Barrett FS, Griffiths RR.

Hum Psychopharmacol. 2017 Jan;32(1). doi: 10.1002/hup.2564. No abstract available.

PMID:
28120488
11.

Effects of caffeine on alcohol reinforcement: beverage choice, self-administration, and subjective ratings.

Sweeney MM, Meredith SE, Evatt DP, Griffiths RR.

Psychopharmacology (Berl). 2017 Mar;234(5):877-888. doi: 10.1007/s00213-017-4528-6. Epub 2017 Jan 20.

12.

An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.

Johnson MW, Garcia-Romeu A, Johnson PS, Griffiths RR.

J Psychopharmacol. 2017 Jul;31(7):841-850. doi: 10.1177/0269881116684335. Epub 2017 Jan 18.

PMID:
28095732
13.

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA.

J Psychopharmacol. 2016 Dec;30(12):1181-1197.

14.

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR.

J Psychopharmacol. 2016 Dec;30(12):1279-1295. Epub 2016 Nov 17.

15.

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR.

J Psychopharmacol. 2016 Dec;30(12):1268-1278. Epub 2016 Aug 30.

16.

Long-term follow-up of psilocybin-facilitated smoking cessation.

Johnson MW, Garcia-Romeu A, Griffiths RR.

Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60. doi: 10.3109/00952990.2016.1170135. Epub 2016 Jul 21. Erratum in: Am J Drug Alcohol Abuse. 2017 Jan;43(1):127.

17.

Weekly Energy Drink Use Is Positively Associated with Delay Discounting and Risk Behavior in a Nationwide Sample of Young Adults.

Meredith SE, Sweeney MM, Johnson PS, Johnson MW, Griffiths RR.

J Caffeine Res. 2016 Mar 1;6(1):10-19.

18.

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Johnson MW, MacLean KA, Caspers MJ, Prisinzano TE, Griffiths RR.

J Psychopharmacol. 2016 Apr;30(4):323-9. doi: 10.1177/0269881116629125. Epub 2016 Feb 15.

19.

Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.

Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, González M, Claramunt J, Barker S, Lomnicka I, Waguespack M, Johnson MW, Griffiths RR, Riba J.

Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii: pyw016. doi: 10.1093/ijnp/pyw016. Print 2016 Jul.

20.

A brief manualized treatment for problematic caffeine use: A randomized control trial.

Evatt DP, Juliano LM, Griffiths RR.

J Consult Clin Psychol. 2016 Feb;84(2):113-21. doi: 10.1037/ccp0000064. Epub 2015 Oct 26.

Supplemental Content

Loading ...
Support Center